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THIS study was designed to examine the influence of a
macrolide  antibiotic,  roxithromycin  (RXM),  on  the
production  of  pro-inflammatory  cytokines,  inter-
leukin (IL)-1b and tumor necrosis factor (TNF)-a . In
the first experiments, we examined the effect of RXM
on  in  vitro cytokine  production  from  lipopolysac-
charide  (LPS)-stimulated  human  peripheral  blood
monocytes.  The  monocytes  were  cultured  in  the
presence of various doses of the agent. After 24 h, the
culture supernatants were obtained and assayed for
IL-1b and TNF-a contents by enzyme-linked immuno-
sorbent assay. RXM suppressed the in vitro produc-
tion of IL-1b and TNF-a in response to LPS stimula-
tion.  This was  dose  dependent  and  first  noted  at  a
concentration of as little as 0.05 m g/ml, which is much
lower  than  therapeutic  blood  levels.  In  the  second
part of the experiments, we examined the influence
of  RXM  on  the  appearance  of  IL-1b and  TNF-a in
mouse lung extract induced by LPS inhalation. RXM
was administered orally into BALB/c mice at a single
dose of 2.5 mg/kg once a day for 5–12 weeks. These
mice were then instilled with LPS into the trachea and
examined for the presence of cytokines in aqueous
lung extracts. Pretreatment of mice with RXM for 5
weeks did not influence of the appearance of both IL-
1b and  TNF-a in  aqueous  lung  extracts.  However,
pretreatment  for  more  than  7  weeks  dramatically
suppressed the cytokine appearance in the extracts.
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Introduction
Sinobronchial syndrome involves the coexistence of
chronic  rhinosinusitis,  and  chronic  lower  airway
inflammation such as chronic bronchitis, bronchiecta-
sis and diffuse panbronchiolitis. In the treatment and
management  of  the  diseases,  we  use  macrolide
antibiotics such as erythromycin, clarithromycin and
roxithromycin  (RXM),  and  satisfactory  results  are
obtained when the patients are given  the agents in
one-half  the  recommended  therapeutic  doses  for
more  than  6  weeks.1 Although  investigation  of  the
mechanisms of improvement has suggested that it is
not  due  to  the  anti-microbiological  effects  of  the
drugs,2,3 the  precise  mechanisms  are  not  well
understood.
Many reports clearly demonstrated that the macro-
lide  antibiotics,  such  as  erythromycin  and  RXM,
strongly inhibit chemotaxis and generation of oxygen
radicals by polymorphonuclear leukocytes when the
cells were cultured in vitro in  the presence of the
macrolides.4–6 It is generally recognized that T cells,
especially helper T cells, play an important role in the
initiation and development of inflammatory diseases
through their secretion of several types of cytokines.
Recently, we have reported that RXM strongly inhibits
the  production  of  inflammatory  cytokines,  inter-
leukin (IL)-3 and IL-4, from human peripheral blood T
cells  in  response  to  in  vitro stimulation  with  con-
canavalin A (Con A).7This inhibitory action of RXM on
T-cell  cytokine  production  was  also  observed  in
vivo:8 the ability of spleen cells to produce inflamma-
tory T-cell  cytokines  such  as  IL-5  was  significantly
suppressed when the cells were prepared from RXM-
pretreated  mice  and  cultured  in  vitro with  Con A.
From these reports, it is reasonable to speculate that
orally  administered  macrolide  antibiotics  inhibit
inflammatory  responses  via  suppression  of  T-cell
cytokine production and results in an improvement of
the clinical status of the patients with sinobronchial
syndrome.
Macrophages play an important role in modulating
the  inflammatory  response,  by  acting  as  scavenger
cells  for  damaged  tissue  components.  These  cells
also  produce  several  inflammatory  cytokines,  espe-
cially  IL-1b and  tumor  necrosis  factor  (TNF)-a .9
However,  the  effect  of  RXM  on  macrophages
remains  unclear.
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unresolved questions regarding the favorable effects of
macrolide  antibiotics  on  inflammatory  diseases  by
examining  the  influence  of  RXM  on  macrophage
cytokine production in vitro and in vivo.
Materials and methods
Mice
Specific pathogen-free, 5-week-old, male BALB/c mice
were purchased from Charles River Japan Inc. (Atsugi,
Japan). To prevent bacterial and fungal airway infec-
tion, they were housed in  filter-barriered cages and
given  autoclaved  food  and  tap  water  ad  libitum
throughout the experiments.
Drugs
RXM  was  kindly  donated  from  Hoechst  Marion
Roussel Co., Ltd., as a water-insoluble pure powder.
The agent was dissolved in methyl alcohol at 50mg/
ml and diluted with phosphate buffered-saline (PBS),
so  as  to  give  a  concentration  of  1.0mg/ml.  This
solution  was  then  filtered  through  a  0.22 m m  filter
(Nihon Millipore Corp., Yonezawa, Japan) and stored
as a stock solution at 4°C until use. For in vitro use, all
dilutions were prepared from this stock solution by
diluting with RPMI-1640 medium supplemented with
10% fetal calf serum, 10mM HEPES, 2 3 10–5M 2ME
(RPMI-FCS).  Metabolized  RXM,  RU28111,  RU39001,
RU44981 and RU45179 were also kindly supplied by
Hoechst Marion Roussel Co., Ltd., as water-insoluble
pure powders. They were dissolved in RPMI-FCS, as in
the case of RXM.
Preparation and purification of human
peripheral blood monocytes
Heparinized peripheral blood was obtained from six
healthy donors who gave written informed consent.
The blood was diluted an equal amount of 0.9% NaCl
and overlayered on Lymphocytes Separation Medium
(Organon  Teknika,  Durham,  NC,  USA).  After  cen-
trifugation  at  1500rpm  for  30min  at  25±2°C,  the
medium–plasma  interface,  which  contained  mono-
nuclear cells, was collected. The cells located in this
fraction were washed five times at 600rpm at 25±2°C
to remove platelets. The resultant cell suspension was
transferred into plastic culture plates and allowed to
attach for 1 h at 37°C. The plates were then washed
vigorously three times with RPMI-FCS to remove non-
adherent cells. The adherent cells were collected by
scraping  with  a  rubber  policeman,  washed  once,
resuspended in RPMI-FCS at a concentration of 2 3
106 cells/ml,  and  used  as  human  peripheral  blood
monocytes  (PBM). The  viability  of  cell  population
exceeded 98%, as judged by trypan blue exclusion,
and peroxidase staining revealed that more than 95%
of cells were monocytes.
Preparation of culture supernatant
An aliquot of cells (1.0ml) was introduced into each
well  of  24-well  plates  containing  1.0ml  of  various
concentrations  of  agents  and  2.0 m g/ml  lipopoly-
saccharide (LPS) extracted from Klebsiella pneumo-
niae (Sigma  Pure  Chemicals,  St.  Louis,  MO,  USA).
After  incubation  for  24h,  the  supernatant  was  col-
lected  after  pelleting  the  cells  by  centrifugation  at
2000rpm for 10min at 25±2°C. The supernatant was
stored  frozen  at  –40°C  until  assayed  for  cytokine
concentration.
Treatment of mice with RXM
Mice were given 2.5mg/kg RXM once a day for 5, 7,
9,  and  12  weeks  via  a  stomach  tube.  In  this
experiment,  the  daily  dose  was  one-half  of  the
recommended therapeutic dose in a patient weighing
60kg. The control mice orally received PBS alone.
Treatment of mice with LPS
LPS (Sigma Pure Chemicals) was dissolved in PBS and
sterilized by passing through a  0.22 m m  filter.  Mice
were  lightly  anesthetized  intraperitoneally  with
0.5mg  pentobarbital,  and  a  middle  incision  was
performed  above  the  sternum.  The  trachea  was
exposed by blunt dissection, a 28-gauge needle was
inserted into the trachea above the carina, and 0.1ml
PBS  containing  various  concentrations  of  LPS  was
injected. Control mice received a similar  volume of
sterile PBS alone.
Preparation of aqueous airway and lung extract
Mice were administered an intraperitoneal injection
of pentobarbital at a dose of 60mg/kg body weight,
24h  after  LPS  injection.  Airway  and  lungs  were
removed and  inflated with 1.0ml PBS and homoge-
nized in 2.0ml PBS using a glass tissue homogenizer
for 60s in an ice-cold water bath. The homogenates
were then centrifuged at 20003 g for 60min at 4°C.
The supernatants were collected and used for aque-
ous airway and lung extract (ALE).
Assay for cytokines
The  activity  of  IL-1b and  TNF-a in  both  culture
supernatants and ALE were examined using commer-
cially available mouse cytokine enzyme-linked immu-
nosorbent  assay  (ELISA) Test  Kits  (GenZyme  Corp.,
Cambridge, MA, USA). The ELISA was performed in
duplicate  according  to  the  manufacturer’s  recom-
mended procedure.
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A statistical evaluation of the data was made with the
Mann–Whitney U test.
Results
Inhibitory effects of RXM on cytokine secretion
from PBM in vitro
To  examine  the  influence  of  RXM  on  cytokine
secretion from PBM in response to LPS stimulation in
vitro, PBM were cultured in the presence of various
concentrations  of  RXM. As  shown  in  Fig.  1,  RXM
caused a dose-dependent reduction of both IL-1b (A)
and TNF-a (B) secretion from PBM in response to LPS
stimulation  in  vitro.  This  suppression  was  first
observed  when  the  cells  were  cultured  in  the
presence  of  RXM  at  a  concentration  of  as  little  as
0.05 m g/ml.  Since  it  is  reported  that  RXM  admin-
istered orally into animals analyzed into four different
metabolized materials,10 the next experiments were
designed  to  examine  whether  metabolized  RXM
could also suppress cytokine secretion from PBM. The
data  in  Fig.  2  clearly  show  that  metabolized  RXM
could  suppress  cytokine  secretion  from  PBM  in  a
dose-dependent  manner.  It  is  also  indicated  that
suppressive  activity  of  metabolized  RXM  on  IL-1b
secretion  (Fig.  2A)  is  stronger  than  that  on TNF-a
secretion (Fig. 2B).
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FIG.  1.  Influence  of  RXM  on  pro-inflammatory  cytokine
production from human PBM in response to LPS stimulation
in vitro. The cells (23 10
6/ml) were cultured in the presence of
various  concentrations of  RXM.  The  culture  supernatants
stimulated with 1.0m g/ml LPS were harvested 24h later. IL-
1b (A) and TNF-a (B) concentrations were assayed by ELISA.
Each data is the mean percent of control (without agent)±SD
of six different subjects.
FIG. 2. Influence of metabolized RXM on pro-inflammatory
cytokine production from human PBM in response to LPS
stimulation in vitro. The cells (23 10
6/ml) were cultured in the
presence of various concentration of metabolized RXM. The
culture  supernatants  stimulated  with  1.0m g/ml  LPS  were
harvested 24h later. IL-1b (A) and TNF-a (B) concentrations
were assayed by ELISA. Each data is the mean percent of
control (without agent) of six different subjects. h : RU28111,
j : RU39001, s : RU44981, d : RU45179.Influence of RXM on cytokine appearance in vivo
This  study  was  designed  to  examine  the  in  vivo
effects of RXM on cytokine secretion. To do this, the
first set of experiments was carried out to investigate
the  influence  of  intratracheal  infusion  of  LPS  on
cytokine levels in ALE. The optimal concentration of
LPS  for  secretion  of  cytokines  into  ALE  was  first
examined by quantitation of IL-1b . The data in Fig. 3
show  that  as  the  concentration  of  LPS  instilled  is
increased, the level of IL-1b in ALE also increases. The
maximum level of IL-1b in ALE was observed with the
use of 1.0 m g/ml LPS, and  the higher concentration
was inhibitory (Fig. 3). The kinetics of IL-1b appear-
ance in ALE was examined in the next experiments.
Mice were instilled intratracheally with 1.0 m g/ml LPS
in  a  volume  of  0.1ml. ALE  was  prepared  from  five
individual  mice various  hours  post-instillation.  Con-
trol ALE  from  five  PBS-instilled  mice  was  similarly
prepared. LPS instillation caused a rapid increase in IL-
1b level, reaching a maximum 24h later, followed by
a slow decrease (Fig. 4). The final set of experiments
was undertaken to examine the influence of RXM on
cytokine appearance in ALE. Mice were orally admin-
istered with 2.5mg/kg RXM once a  day  for various
periods. During the course of RXM treatment, mice
were intratracheally infused with 1.0m g/ml LPS, and
ALE was prepared 24h after LPS infusion.
As shown in Fig. 5A, short-term (within 5 weeks)
administration of RXM into mice did not influence the
appearance of IL-1b in ALE induced by LPS stimula-
tion.  On  the  other  hand,  long-term  (more  than  7
weeks)  administration  of  RXM  dramatically  sup-
pressed the appearance of IL-1b in ALE. The data in
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FIG. 3. Dose–response profile of the effect of LPS instillation
on IL-1b appearance in ALE. Various concentrations of LPS in
a volume of 0.1ml were injected intratracheally in BALB/c
mice. An ALE was prepared from mice 24h later. Each data
represents the mean±SD of five individual mice of one of two
different  experiments with  reproducible  results.  N.S.:  not
significant
FIG. 4. Kinetics of IL-1b appearance in ALE induced by intratracheal injection with 1.0m g/ml LPS in a volume of 0.1ml. An ALE
was prepared from five individual mice at different time intervals after intratracheal instillation. Each value represents the
mean±SD of five individual mice of one of two different experiments with reproducible results. * P<0.05, ** P<0.001, h : PBS-
instilled mice, j : LPS-instilled mice.Fig.  5B  clearly  show  that  the  influence  of  RXM
administration on TNF-a appearance in ALE is similar
to  that  in  IL-1b :  the  level  of  TNF-a in  ALE  was
markedly suppressed when donor mice were treated
orally  with  RXM  for  more  than  7  weeks,  but  not
within 5 weeks.
Discussion
The present results clearly demonstrate that RXM and
metabolized RXM strongly inhibit cytokine secretion
from human PBM in response to mitogenic stimula-
tion in vitro, and that the minimum concentration of
agents that causes inhibition of cytokine secretion is
as little as 0.05m g/ml (Figs 1 and 2).
Pharmacological  studies  revealed  rapid  and  com-
plete absorption of RXM administered orally, resulting
in high plasma levels and in prolonged half-life, since
the  macrocycline  of  RXM  is  locally  modified  to
prevent  inactivation  in  gastric  juice.10 It  is  also
reported that, after oral administration, plasma levels
of  RXM  were  gradually  increased  and  attained  a
plateau  at  a  concentration  of  approximately
10.0 m g/ml.10 RXM in plasma was then analyzed into
four different metabolized materials, and metabolized
materials  except  for  two  types,  RU44981  and
RU45179, are excreted into urine and feces,10 suggest-
ing  that  an  increase  in  unmetabolized  and  hardy
excreted metabolized RXM may occur progressively.
Together with the present results, it may be suggested
that RXM inhibits human monocyte activation, espe-
cially  cytokine  secretion,  and  helps  to  favorably
modify the clinical conditions of patients with sino-
bronchial  syndrome.  However,  before  drawing  the
conclusion that the ability of RXM to inhibit cytokine
secretion  is  responsible  for  the  beneficial  effect  of
macrolides on sinobronchial syndrome, it is necessary
to examine whether suppressive activity of RXM on
cytokine secretion could also be observed in vivo.
Endotoxins, LPS components of gram-negative bac-
teria,  are  known  to  be  important  stimuli  in  the
development of inflammatory responses.11,12 Pauwels
et  al.  reported  that  inhalation  of  aerosolized  endo-
toxin  causes  pulmonary  inflammatory  responses  in
rats.13 It has also been reported that endotoxins can
stimulate various inflammatory cells, including mac-
rophages, and may induce the release of a variety of
inflammatory  mediators,  such  as  IL-1b and  TNF-
a .11–13 Therefore,  we  used  an  endotoxin/mouse
system  and  carried  out  the  next  experiments. The
data in Figs 3–5 clearly demonstrate that intratracheal
injection of LPS causes the appearance of inflamma-
tory  cytokines  in  airways  and  lungs,  which  was
inhibited by pretreatment of mice with RXM. These
results may suggest that RXM orally administered into
mice  inhibits  inflammatory  cytokine  secretion  in
airways and results in attenuating effects on sinobron-
chial syndrome.
Although the present results suggest that macrolide
antibiotics inhibit  macrophage activation, especially
cytokine secretion, and result in a favorable modifica-
tion of the clinical status of patients with sinobron-
chial  syndrome,  the  mechanisms  by  which  RXM
inhibits cytokine secretion  in vitro and in vivo are
not clear at present. It is possible that RXM binds to
receptors  such  as  immunophillin,  which  is  the
intracellular receptor of immunosupressive agents FK-
506 and rapamycin, and the complexes interfere with
cytokine  gene  transcription,14,15 resulting  in  inhibi-
tion  of  cytokine  secretion. This  suggestion  may  be
supported by our previous experiments showing that
RXM could suppress mRNA  expression  of TNF-a in
human  peripheral  blood monocytes  when  the  cells
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FIG. 5. Inhibition of pro-inflammatory cytokine appearance in
aqueous lung extracts prepared from mice pretreated with
RXM. BALB/c mice were orally administered with 2.5mg/kg
RXM for various periods. Mice were injected intratracheally
with 1.0m g/ml LPS in a volume of 0.1ml. After 24h, lungs
were obtained and homogenized in 1.0ml PBS to examine
the  concentration  of  IL-1b (A)  and  TNF-a (B).  Cytokine
concentrations were assayed by ELISA, and the results were
expressed as mean percent of control (PBS-instilled)±SD of
five individual mice. s : treated with vehicle alone, d : treated
with RXM. *P<0.001, **P<0.05.were cultured in vitro with the agent.16 Furthermore,
our  unpublished  data  also  revealed  the  inhibitory
action of RXM on macrophage growth and maturation
from its precursors in vitro, suggesting that inhibition
of  in  vivo macrophage  cytokine  secretion  by  RXM
may be due to, at least partly, its suppressive activity
on macrophage growth. In any case, more in-depth
analysis  of  the  relationship  between  inhibition  of
secretion  of  inflammatory  mediators  by  macrolides
and  inflammatory  responses  should  allow  us  to
identify  the  precise  mechanisms  involved  in  the
therapeutic  mode  of  action  of  macrolides  on  sino-
bronchial syndrome.
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